.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XX12_Lefamulin.Lefamulin_1 .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XX12_Lefamulin.Lefamulin_1| name: | Lefamulin_1 |
| ATC code: | J01XX12_1 | route: | oral |
| n-compartments | 2 |
Lefamulin is a pleuromutilin class antibiotic indicated for the treatment of community-acquired bacterial pneumonia (CABP) in adults. It is approved and used clinically and possesses activity against a range of Gram-positive and atypical bacterial pathogens.
Pharmacokinetics in healthy adult subjects following oral administration (fasted state).
Zhang, L, et al., & Rubino, CM (2019). Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods. The Journal of antimicrobial chemotherapy 74(Suppl 3) iii27–iii34. DOI:10.1093/jac/dkz088 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30949708
Bian, X, et al., & Zhang, J (2024). Lefamulin dosing optimization using population pharmacokinetic and pharmacokinetic/pharmacodynamic assessment in Chinese patients with community-acquired bacterial pneumonia. Frontiers in pharmacology 15 1456741–None. DOI:10.3389/fphar.2024.1456741 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39525637
Bhavnani, SM, et al., & Ambrose, PG (2019). Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia. The Journal of antimicrobial chemotherapy 74(Suppl 3) iii35–iii41. DOI:10.1093/jac/dkz089 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30949705